NEW HIGHLIGHT
Vizimpro

Vizimpro

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Dacomitinib
Indications/Uses
1st-line treatment of patients w/ metastatic non-small cell lung cancer (NSCLC) w/ epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations.
Dosage/Direction for Use
45 mg once daily until disease progression or unacceptable toxicity occurs.
Administration
May be taken with or without food: Take at the same time each day.
Contraindications
Special Precautions
Discontinue use if interstitial lung disease occurs. Diarrhea; dermatologic reactions. Limit sun exposure. Avoid concomitant use w/ proton-pump inhibitors. May affect ability to drive & use machines. Not recommended in severe hepatic & renal impairment. Women of childbearing potential should use effective contraception during & at least 17 days after last dose. Not to be used during pregnancy & lactation. Paed <18 yr.
Adverse Reactions
Diarrhea, stomatitis, nausea, constipation, mouth ulceration; rash, paronychia, dry skin, alopecia, pruritus, palmar-plantar erythrodysesthesia syndrome, dermatitis; decreased appetite & wt; cough, nasal mucosal disorder, dyspnea, upper resp tract infection, chest pain; conjunctivitis; pain in extremity, musculoskeletal pain; asthenia; insomnia; anemia, lymphopenia; hypoalbuminemia, increased ALT & AST, hyperglycemia, hypocalcemia, hypokalemia, hyponatremia, increased creatinine & alkaline phosphatase, hypomagnesemia, hyperbilirubinemia.
Drug Interactions
Decreased conc w/ proton-pump inhibitors. Increased conc of CYP2D6 substrates.
ATC Classification
L01XE47 - dacomitinib ; Belongs to the class of protein kinase inhibitors, other antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Vizimpro FC tab 15 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in